Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy  by Rapacciuolo, Antonio et al.
EXPERIMENTAL STUDIES
Important Role of Endogenous Norepinephrine
and Epinephrine in the Development of
In Vivo Pressure-Overload Cardiac Hypertrophy
Antonio Rapacciuolo, MD,* Giovanni Esposito, MD,* Kathleen Caron, PHD,† Lan Mao, MD,*
Steven A. Thomas, MD, PHD,‡ Howard A. Rockman, MD*
Durham and Chapel Hill, North Carolina and Philadelphia, Pennsylvania
OBJECTIVES We sought to define the role of norepinephrine and epinephrine in the development of
cardiac hypertrophy and to determine whether the absence of circulating catecholamines
alters the activation of downstream myocardial signaling pathways.
BACKGROUND Cardiac hypertrophy is associated with elevated plasma catecholamine levels and an increase
in cardiac morbidity and mortality. Although considerable evidence suggests that G-protein–
coupled receptors are involved in the hypertrophic response, it remains controversial whether
catecholamines are required for the development of in vivo cardiac hypertrophy.
METHODS We performed transverse aortic constriction (TAC) in dopamine beta-hydroxylase knockout
mice (Dbh2/2, genetically altered mice that are completely devoid of endogenous norepi-
nephrine and epinephrine) and littermate control mice. After induction of cardiac hypertro-
phy, the mitogen-activated protein kinase (MAPK) signaling pathways were measured in
pressure-overloaded/wild-type and Dbh2/2 hearts.
RESULTS Compared with the control animals, cardiac hypertrophy was significantly blunted in Dbh2/2
mice, which was not associated with altered cardiac function, as assessed by transthoracic
echocardiography in conscious mice. The extracellularly regulated kinase (ERK 1/2),
c-jun–NH2-terminal kinase (JNK) and p38 MAPK pathways were all activated by two- to
threefold after TAC in the control animals. In contrast, induction of the three pathways
(ERK 1/2, JNK and p38) was completely abolished in Dbh2/2 mice.
CONCLUSIONS These data demonstrate a nearly complete requirement of endogenous norepinephrine
and epinephrine for the induction of in vivo pressure-overload cardiac hypertrophy and
for the activation of hypertrophic signaling pathways. (J Am Coll Cardiol 2001;38:876–82)
© 2001 by the American College of Cardiology
Cardiac hypertrophy occurs in response to increased stress
on the heart. Although the development of myocardial
hypertrophy is believed to be a compensatory mechanism to
normalize wall stress and maintain normal cardiac function,
epidemiologic studies have shown an association between
ventricular hypertrophy and increased cardiac morbidity and
mortality (1). Therefore, investigations that lead to a better
understanding of the molecular signals that stimulate myo-
cyte growth would have clear therapeutic implications for
diseases characterized by cardiac hypertrophy. In this re-
gard, considerable evidence suggests that G-protein–
coupled receptors are involved in the hypertrophic response
(2); however, the precise ligands and receptors that are most
involved are largely unknown. Catecholamines are one
possibility, because they work through G-protein–coupled
receptors and are clearly relevant to maintain cardiac func-
tion in both health and disease. Nonetheless, whether
catecholamines are required for the development of in vivo
cardiac hypertrophy remains controversial (3).
Studies in both cultured neonatal rat cardiomyocytes (4)
and experimental animals (5) have suggested that stimula-
tion by catecholamines can produce a hypertrophic pheno-
type. In contrast, in vitro (6) and in vivo studies (7) have
suggested that catecholamines are not important mediators
of the hypertrophic response. To date, studies of gene-
targeted mice have not resolved the issue of whether
intracellular signals resulting from catecholamine stimula-
tion are important for cardiac growth. For example, trans-
genic mice with cardiac overexpression of either the wild-
type beta1b-adrenergic receptor (AR) or beta2-AR did not
result in cardiac hypertrophy (8,9). Likewise, cardiac weight
was unaffected in gene-targeted adult mice with disruption
of genes encoding the alpha1b-AR, alpha1c-AR or beta1-AR
(10–12).
To determine whether catecholamines are required for
the development of cardiac hypertrophy, we tested whether
genetically altered mice that lack endogenous norepineph-
rine and epinephrine are able to develop cardiac hypertrophy
in response to in vivo pressure overload. These mice have
been created by targeted deletion of the dopamine beta-
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hydroxylase gene (Dbh2/2), the essential enzyme in the
biosynthetic pathway converting dopamine to norepineph-
rine (13,14). This model has the advantage of totally
eliminating norepinephrine and epinephrine, while preserv-
ing the release of co-transmitters and other factors derived
from the sympathetic nervous system or adrenal gland, or
both. By measuring the response to transverse aortic con-
striction (TAC) in Dbh2/2 and littermate control mice, we
are able to definitively assess the role of norepinephrine and
epinephrine in the development of cardiac hypertrophy and
induction of downstream signaling pathways.
METHODS
Experimental animals. Adult (4 to 5 months old) dopa-
mine beta-hydroxylase knockout mice (Dbh2/2) were used
in this study. Age-matched littermate heterozygotes
(Dbh1/2) were used as control animals. These Dbh1/2 mice
have been extensively characterized and shown to have
normal levels of norepinephrine and epinephrine (13,14).
The animals in this study were handled according to
approved protocols and animal welfare regulations by the
Institutional Review Board of Duke University Medical
Center.
Echocardiography in conscious animals. Transthoracic
two-dimensional guided M-mode echocardiography
was performed, using an HDI 5000 echocardiograph
(ATL, Bothell, Washington), in conscious mice, as
previously described (15). In separate conscious Dbh2/2
mice, echocardiography was performed before and 5 h
after the subcutaneous administration of L-threo-3,4-
dihydroxyphenylserine (L-DOPS) (0.4 mg/g) to transiently
restore norepinephrine levels. DOPS is a synthetic amino
acid that is converted to norepinephrine by aromatic
L-amino-acid decarboxylase, which completely restores tis-
sue and circulating norepinephrine levels after dorsal sub-
cutaneous injection (16).
Transverse aortic constriction. After conscious echocar-
diography, mice were anesthetized and TAC or a sham
operation was performed, as previously described (17,18).
Seven days after the operation, conscious echocardiography
was again performed, and the trans-stenotic gradient sys-
tolic pressure was assessed (17,18). The hearts were then
excised; the chambers were dissected free and weighed and
then frozen in liquid nitrogen. There was no difference in
post-TAC mortality between the control and Dbh2/2 mice.
In separate anesthetized control and Dbh2/2 mice,
intravenous infusion of either saline, angiotensin II
(0.2 mmol/min) or norepinephrine (0.02 mmol/min) was
administered through the jugular vein for 7 to 10 min, while
monitoring arterial pressure. The dose of angiotensin II and
norepinephrine was chosen to achieve a 50% increase in
blood pressure. After infusion, the hearts were harvested
and immediately frozen in liquid nitrogen for determination
of mitogen-activated protein kinase (MAPK) activity.
Mitogen-activated protein kinase assays. The MAPK
assays were performed on myocardial extracts from the left
ventricles of the mice, as previously described (19). After
immunoprecipitation with antibodies specific for the various
MAPKs, reactions were performed in 20 mmol/liter of
adenosine triphosphate (ATP), (g-32P)ATP (20 mCi/ml)
and myelin basic protein (0.25 mg/ml) for extracellularly
regulated kinase (ERK)/p38 or GST–c-jun (10 mg) for
c-jun–NH2-terminal kinase (JNK) and incubated at 30°C
for 20 min, then terminated by adding 40 ml of 23
Laemmli buffer. Phosphorylated myelin basic protein and
GST–c-jun were resolved by polyacrylamide gel electro-
phoresis and quantified with a phosphorimager.
Quantitative measurement of kidney renin ribonucleic
acid (RNA). Total kidney RNA was prepared using
TRIzol reagent (GibcoBRL, Grand Island, New York),
according to manufacturer’s instructions. Amounts of
renin RNA per 0.5 mg of total RNA were determined
using the ABI 7700 real-time reverse-transcription poly-
merase chain reaction system (Perkin Elmer Applied Biosys-
tems, Foster, California). Primers and Taqman probes were
determined by using Primer Express software (Perkin Elmer
Applied Biosystems). The primers and sequences for renin
amplification were RenF-59-ACAGTATCCCAACAG-
GAGAGACAAG-39; and RenR-59-CACCCAGGACCC-
AGACA-39. The renin Taqman probe sequence was 59-
FAM-TGGCTCTCCATGCCATGGACATCC-Tamra-
39. Beta-actin was used as the internal standard control
agent in each sample. The primers and sequences for beta-actin
amplification were beta-actinF-59-CTGCCTGACGGC-
CAAGTC-39; and beta-actinR-59-CAAGAAGGAAGG-
CTGGAAAAGA-39. The beta-actin Taqman probe se-
quence was 59-TET-CACTATTGGCAACGAGCGGTT-
CCG-Tamra-39. Each sample was measured twice.
Statistical analysis. Data are expressed as the mean
value 6 SEM. For comparison of the echocardiographic
variables before and after TAC or treatment with L-DOPS,
twice repeated measures analysis of variance (ANOVA) was
used. When appropriate, post hoc analysis was performed
using the Scheffe´ test. Analysis of the slopes of the regres-
sion lines for the relationship between cardiac mass and
pressure gradient was performed using a test of parallelism
Abbreviations and Acronyms
AR 5 adrenergic receptor
BW 5 body weight
Dbh2/2 5 dopamine beta-hydroxylase knockout mice
ERK 5 extracellularly regulated kinase
%FS 5 percent fractional shortening
JNK 5 c-jun–NH2-terminal kinase
L-DOPS 5 L-threo-3,4-dihydroxyphenylserine
LV 5 left ventricular
LVW 5 left ventricular weight
MAPK 5 mitogen-activated protein kinase
TAC 5 transverse aortic constriction
TL 5 tibial length
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by multivariate ANOVA. For heart weight and kinase
activity data, unpaired t tests were performed. For all
analyses, p , 0.05 was considered significant.
RESULTS
Evaluation of the hypertrophic response seven days after
aortic constriction. To evaluate the hypertrophic response
after TAC, we measured the increase in the left ventricular
weight (LVW) to body weight (BW) ratio and the LVW to
tibial length (TL) ratio after seven days of in vivo pressure
overload. Seven days after TAC, control mice with normal
norepinephrine and epinephrine levels developed significant
left ventricular (LV) hypertrophy, with a 60% increase in the
LVW/BW ratio and a 62% increase in the LVW/TL ratio,
compared with sham-operated control mice. This degree of
cardiac hypertrophy was induced with a mean trans-stenotic
systolic pressure gradient of 70.7 6 5.6 mm Hg (Table 1,
Fig. 1). In marked contrast, the hypertrophic response after
TAC was significantly blunted in the littermate Dbh2/2
mice compared with those undergoing a sham operation, as
measured by LVW/BW (19.7%) or LVW/TL (14%), even
though the trans-stenotic pressure gradient remained elevated
at 67.9 6 5.5 mm Hg (Table 2, Fig. 1). In addition, peak LV
systolic pressure, as measured by the carotid artery pressure
proximal to the stenosis, was not different in the Dbh2/2 mice
compared with the control mice (174 6 8.2 vs. 172 6 5.6 mm
Hg), indicating that the two groups of banded mice had
matched hemodynamic loads. The LVW/BW and LVW/TL
ratios in the sham-operated animals were not different between
the two groups (Tables 1 and 2, Fig. 1).
The impaired hypertrophic response in the Dbh2/2 mice
occurred over a wide range of pressures, as shown in Figure
2. In the control group, a strong correlation between the
index LV mass (LVW/BW) and trans-stenotic systolic
pressure gradient was observed (Fig. 2). In contrast, Dbh2/2
mice showed no relationship between the pressure load and
degree of hypertrophy (Fig. 2).
Evaluation of cardiac function before and after aortic
constriction. To eliminate the effect of anesthesia on LV
performance, we evaluated LV function by echocardiogra-
phy in conscious mice. As shown in Table 1, seven days of
pressure overload in control mice did not affect the chamber
diameters or percent fractional shortening (%FS). Septal
wall thickness was increased, consistent with the induction
of concentric LV hypertrophy after pressure overload.
Although the hypertrophic response was blunted in the
Dbh2/2 mice, cardiac function after TAC remained normal.
The Dbh2/2 mice showed no change in LV end-diastolic
dimension after TAC. Furthermore, a small but significant
increase in %FS after TAC was found in the Dbh2/2 mice, as
measured by noninvasive echocardiography (Table 2). Lower
basal %FS, heart rate and heart rate–corrected mean velocity of
circumferential fiber shortening (Vcfc) in the pre-TAC
Dbh2/2 mice are also shown in Table 2, compared with the
pre-TAC littermate control animals (Table 1).
To determine whether the reduced basal cardiac function
in the Dbh2/2 mice reflects a developmental defect caused
by norepinephrine deficiency, or one that results from a
physiologic deficit of norepinephrine, we quickly restored
norepinephrine levels by administering L-DOPS to sepa-





Before After Before After
Physiologic variables
BW (g) 31.92 6 1.87 30.77 6 1.96* 32.13 6 1.85 29.76 6 1.77*
LVW/BW ratio (mg/g) 3.04 6 0.05 4.86 6 0.28†
LVW/TL ratio (mg/mm) 5.1 6 0.33 8.27 6 0.68†
TSPG (mm Hg) 70.7 6 5.6
LV/BW vs. sham operation
(% change)
60




LVEDD (mm) 3.36 6 0.12 3.25 6 0.07
LVESD (mm) 1.80 6 0.11 1.65 6 0.09
FS (%) 46.8 6 2.23 49.8 6 2.22
SWT (mm) 0.79 6 0.05 1.0 6 0.06‡
PWT (mm) 0.76 6 0.04 0.79 6 0.05
HR (beats/min) 562 6 38 592 6 19
Mean Vcfc (circ/s) 2.64 6 0.15 2.83 6 0.17
*p , 0.05 for after vs. before either sham operation or TAC; †p , 0.001 for after TAC vs. after sham operation; ‡p , 0.005
for after TAC vs. before TAC. Data are presented as the mean value 6 SEM.
BW 5 body weight; %FS 5 percent fractional shortening, calculated as (LVEDD 2 LVESD)p100/LVEDD; HR 5 heart
rate; LVEDD 5 left ventricular end-diastolic dimension; LVESD 5 left ventricular end-systolic dimension; LVW 5 left
ventricular weight; PWT 5 posterior wall thickness; SWT 5 septal wall thickness; TAC 5 transverse aortic constriction; TL 5
tibial length; TSPG 5 trans-stenotic systolic pressure gradient, calculated as the difference between right and left carotid artery
systolic pressure; Vcfc 5 heart rate–corrected mean velocity of circumferential fiber shortening, calculated as fractional
shortening divided by ejection time multiplied by the square root of the R-R interval.
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rate out Dbh2/2 mice, and then we measured cardiac
function. DOPS is a synthetic amino acid that is converted
to norepinephrine by aromatic L-amino-acid decarboxylase
and restores tissue and circulating norepinephrine levels in
the mouse 5 h after subcutaneous injection (16). As shown
in Table 3, LV end-systolic dimension, heart rate, mean
Vcfc and %FS significantly increased in the Dbh2/2 mice
5 h after the early administration of DOPS. These results
indicate that differences in basal function between control
Figure 1. Effect of pressure overload on development of cardiac hypertro-
phy in control and Dbh2/2 mice. (a) The LVW/BW ratio was measured
in control and Dbh2/2 mice seven days after either a sham operation or
TAC. *p , 0.00001 for TAC control group vs. sham operation control
group. †p , 0.005 for TAC control group vs. TAC Dbh2/2 group. ‡p ,
0.01 for TAC Dbh2/2 group vs. sham operation Dbh2/2 group. (b) The
LVW/TL ratio was used as an index of the hypertrophic response after
TAC. *p , 0.001 for TAC control group vs. either sham operation control
group or TAC Dbh2/2 group. Sham operation control group (n 5 12);
TAC control group (n 5 13); sham operation Dbh2/2 group (n 5 13); and
TAC Dbh2/2 group (n 5 11). Data are from the control and Dbh2/2 mice
with pressure gradients .40 mm Hg.





Before After Before After
Physiologic variables
BW (g) 28.03 6 1.74 27.66 6 1.79* 26.64 6 1.00 25.57 6 0.77*
LVW/BW ratio (mg/g) 2.94 6 0.14 3.52 6 0.14†
LVW/TL ratio (mg/mm) 4.45 6 0.18 5.07 6 0.24
TSPG (mm Hg) 67.9 6 5.52
LV/BW vs. sham operation
(% change)
19.7




LVEDD (mm) 3.36 6 0.10 3.32 6 0.08
LVESD (mm) 2.18 6 0.10‡ 1.95 6 0.10
FS (%) 35.3 6 1.53‡ 41.6 6 1.98§
SWT (mm) 0.70 6 0.04 0.82 6 0.03
PWT (mm) 0.68 6 0.02 0.75 6 0.01
HR (beats/min) 426 6 13‡ 433 6 11
Mean Vcfc (circ/s) 2.11 6 0.09‡ 2.42 6 0.14
*p , 0.05 for after vs. before either sham operation or TAC. †p , 0.05 for after TAC vs. after sham operation. ‡p , 0.005 for
after TAC vs. before Dbh2/2 mice vs. before TAC in control mice (see Table 1). §p , 0.05 for after TAC vs. before TAC. Data
are presented as the mean value 6 SEM. As a group, LVESD, %FS, SWT and HR were significantly different in the Dbh mice
compared with the control mice at baseline (p , 0.01 by ANOVA).
Abbreviations as in Table 1.
Figure 2. Relationship between pressure load and induction of cardiac
hypertrophy for all banded mice. The index of LV mass (LVW/BW) is
plotted against the trans-stenotic systolic pressure gradient produced by
TAC for all of the banded control (n 5 17, solid circles) and Dbh2/2 (n 5
17, open circles) animals. Linear regression analysis was significant for the
control mice (y 5 0.0286x 1 2.8325, r 5 0.66, p , 0.01 by ANOVA), but
not for the Dbh2/2 mice (0.0032x 1 3.2665, r 5 0.20, p 5 NS). The
slopes of the two regression lines were significantly different (p , 0.005) by
multivariate ANOVA.
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and Dbh2/2 mice are the result of the physiologic loss of
norepinephrine, rather than being secondary to a fixed
developmental abnormality.
Role of norepinephrine and epinephrine in pressure-
overload–induced MAPK activation. In hearts from six
sham and six TAC control animals, the activity of ERK 1/2,
JNK, p38 and p38-beta was evaluated seven days after the
operation. As shown in Figure 3, a significant increase in
activity of the three known MAPK pathways was found
after TAC in hypertrophied control mice. In contrast,
despite a comparable and persistent pressure load in the Dbh2/2 mice, the induction of ERK 1/2, p38, p38-beta and
JNK activation was completely abolished (Fig. 3). In a
separate set of animals, the basal MAPK activity was not
found to be different between the control group and the
Dbh2/2 group (n 5 3 each).
To test whether the MAPK pathways in the hearts of
Dbh2/2 mice could respond to the exogenous administra-
tion of neurohormones, MAPK activity was assessed after a
7- to 10-min infusion of either norepinephrine or angio-
tensin II in separate Dbh2/2 and control mice. As shown in
Figure 4, a robust increase in ERK and JNK MAPK activity
was seen in the Dbh2/2 mice, which was equal to or even
greater than that observed in the control mice. Neither p38
nor p38-beta was activated by short infusion of norepineph-
rine or angiotensin II in either control or Dbh2/2 mice.
These data demonstrate that the hearts of Dbh2/2 mice are
able to respond to extracellular signals that activate MAPK
pathways and support our hypothesis that endogenous
norepinephrine and epinephrine are required for the devel-
opment of cardiac hypertrophy in response to in vivo
pressure overload.
Activation of the renin-angiotensin system after aortic
constriction. The sympathetic nervous system is a very
potent stimulatory factor for the control of renin secretion,
which is mediated primarily by stimulation of beta1-ARs on
juxtaglomerular cells (20). To determine whether the sym-
pathetic nervous system plays a prominent role in activation
of the renin-angiotensin system during development of in
vivo pressure-overload cardiac hypertrophy, renal renin
messenger RNA (mRNA) levels were measured by real-
time reverse-transcription polymerase chain reaction. It has
Figure 3. Effect of pressure overload on activation of MAPK pathways.
Representative autoradiograms and summary data of MAPK activity for
each of the three major pathways are shown. (a) ERK 1/2: *p , 0.0005 for
sham operation control group vs. TAC control group. (b) JNK 1/2: *p ,
0.0001 for sham operation control group vs. TAC control group. (c) p38:
*p , 0.0005 for sham operation control group vs. TAC control group.
(d) p38b: *p , 0.001 for sham operation control group vs. TAC control
group. p 5 NS for sham operation Dbh2/2 group vs. TAC Dbh2/2 group
for the aforementioned MAPKs.
Figure 4. Effect of exogenous administration of norepinephrine (NE) and
angiotensin II (Ang II) on activation of the MAPK pathways. Represen-
tative autoradiograms for each of the three major MAPK pathways are
shown. The increase in ERK and JNK activity in the hearts of Dbh2/2
mice after infusion of norepinephrine and angiotensin II was equal to or
greater than that of the control hearts.
Table 3. Echocardiographic Variables in Dbh2/2 Mice
Before and After Repletion of Norepinephrine
with L-Threo-3,4-Dihydroxyphenylserine
Before After
LVEDD (mm) 3.30 6 0.09 3.14 6 0.05
LVESD (mm) 2.11 6 0.12 1.43 6 0.10*
FS (%) 36.11 6 2.83 54.67 6 2.36*
SWT (mm) 0.61 6 0.04 0.69 6 0.06
PWT (mm) 0.51 6 0.03 0.57 6 0.04
HR (beats/min) 405 6 23 578 6 23*
Mean Vcfc (circ/s) 2.12 6 0.12 4.01 6 0.22*
Echocardiography was performed in conscious mice (n 5 7) before and 5 h after the
dorsal subcutaneous injection of L-threo-3,4-dihydroxyphenylserine (L-DOPS,
0.4 mg/g). *p , 0.005 for after vs. before L-DOPS. Data are presented as the mean
value 6 SEM.
Abbreviations as in Table 1.
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been shown that renal renin mRNA levels accurately reflect
homeostatic changes in the renin-angiotensin system (21).
As shown in Figure 4, the renin level was significantly
increased (2.5-fold) in the banded control mice compared
with the sham-operated animals, indicating a robust activa-
tion of the renin-angiotensin system after TAC. In contrast,
no increase in kidney renin levels was found after aortic
banding in the Dbh2/2 animals (Fig. 5).
DISCUSSION
The main purpose of this study was to define the role of
norepinephrine and epinephrine in the development of
cardiac hypertrophy and to determine whether the absence
of circulating norepinephrine and epinephrine alters the
activation of downstream signaling pathways. The first
finding is that endogenous norepinephrine and epinephrine
are required, to a large extent, for the development of
cardiac hypertrophy in response to the physiologic stress of
pressure overload. Most likely, this is the result of both a
direct effect of norepinephrine and epinephrine on cardiac
adrenergic receptors and an indirect effect through stimu-
lation of renal renin release. Although autonomic regulation
of cardiac contractile function is important, sympathetic
nervous system hyperactivity can also initiate or accelerate
cardiovascular pathology. The detrimental effects of cat-
echolamines are likely due, in part, to the induction of
myocyte apoptosis by chronic beta-AR stimulation (22).
Role of norepinephrine and epinephrine in development
of cardiac hypertrophy. Early studies by Simpson (4)
showed that cultured neonatal rat cardiomyocytes respond
to norepinephrine stimulation, with an increase in myocyte
size. Furthermore, long-term infusion of catecholamines in
experimental animals can induce cardiac hypertrophy (5). In
contrast, in experiments using loaded and unloaded papil-
lary muscles in a cat model of ventricular overload, Cooper
et al. (7) showed that catecholamines may not be important
mediators of the hypertrophic response. Other studies (6)
have also supported the conclusion that mechanical factors
predominate in the development of cardiac hypertrophy,
and, while catecholamines may play a role, their importance
is not certain (3). The data from the present study clearly
establish the important role of norepinephrine and epineph-
rine in the induction of cardiac hypertrophy and suggests
that blocking the action of norepinephrine and epinephrine
would not only be favorable with regard to cell survival, but
it would also inhibit cardiac hypertrophy.
Role of norepinephrine and epinephrine on induction of
MAPK activity. The second finding is that induction of a
hypertrophic response is associated with activation of the
three major MAPK pathways, and these MAPK signaling
pathways may be activated both directly and indirectly by
norepinephrine and epinephrine. G-protein–coupled recep-
tors and G proteins are involved in regulation of the
hypertrophic response through activation of MAPK path-
ways (19,23). Among the G proteins, Gq has been shown to
be associated with the development of in vivo cardiac
hypertrophy (17,24) and induction of MAPK activity,
particularly ERK and JNK (19). A variety of ligands can
activate Gq-coupled receptors, such as the alpha1-AR (nor-
epinephrine and phenylephrine), the angiotensin II type-1a
receptor (AT1a) and endothelin-1 receptor, which have all
been shown to trigger cellular hypertrophy in cultured
neonatal rat ventricular myocytes (4,25,26). The role of
beta-ARs in the development of cardiac hypertrophy is
more controversial. Early in vitro studies did not show that
beta-AR stimulation contributes to myocyte hypertrophy
(4), whereas more recent studies suggest that beta-AR
stimulation can lead to both cellular hypertrophy and
MAPK activation (27,28). In this regard, recent evidence
suggests that the phosphorylated beta-ARs can activate the
ERK pathway by switching coupling to the G protein called
Gi, a process that involves the beta-gamma subunits (29).
Activation of the renin-angiotensin system by norepi-
nephrine and epinephrine. The small residual hypertro-
phy observed in the pressure overloaded Dbh2/2 mice could
be due to autocrine or paracrine signaling mediated by
fibroblast growth factor-2 (30) and/or other peptide growth
factors, such as angiotensin II and endothelin I. Although it
is interesting to note that the AT1a knockout mice still
develop robust hypertrophy in response to pressure overload
(31,32), supporting our data of an important role for
catecholamines, it is possible that signaling through either
AT1b (33) or AT2 (34) receptors is sufficient for the
development of hypertrophy. However, it is unlikely that
the circulating renin-angiotensin system is responsible for
the low residual hypertrophy in the Dbh2/2 mice, on the
basis of our third finding in this study. That is, endogenous
norepinephrine and epinephrine are necessary for the acti-
vation of the renin-angiotensin system after imposition of
mechanical pressure overload. Previous work has shown that
release of renin from juxtaglomerular cells is under the
control of beta1-adrenergic stimulation (20). In this study,
Figure 5. Role of norepinephrine and epinephrine in regulating activation
of the renin-angiotensin system after aortic constriction. The renal renin
messenger ribonucleic acid (mRNA) level was significantly increased in the
banded control mice compared with the sham-operated mice, but not in
the banded Dbh2/2 mice. *p , 0.001 for sham operation control group vs.
TAC control group; p 5 NS for sham operation Dbh2/2 group vs. TAC
Dbh2/2 group. Sham operation: n 5 6 in control group and n 5 4 in
Dbh2/2 group; TAC: n 5 4 in control group and n 5 6 in Dbh2/2 group.
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we show that renin release, in response to hemodynamic
stress, is dependent on activation of the sympathetic nervous
system. It is interesting that the basal renin levels were
normal in the Dbh2/2 mice, suggesting that under normal
homeostatic conditions, regulation of the renin-angiotensin
system does not require endogenous norepinephrine or
epinephrine.
It has been previously demonstrated that LV mass in
normotensive and hypertensive patients is closely coupled to
an increased cardiac sympathetic activity (35). In the same
study, arterial blood pressure did not correlate with LV mass
(35). Data from our study suggest that normalization of
cardiac sympathetic tone is extremely important to reduce or
prevent LV hypertrophy. Finally, this model will be valuable
to determine whether preventing cardiac hypertrophy has
adverse long-term consequences on cardiac function.
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